February 1, 1993Arteriosclerosis and Thrombosis A Journal of Vascular BiologyOpen Access

Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations.

View Full Paper

Ask AI

Bookmark

Why the study?

Does recombinant human growth hormone treatment alter lipid and apolipoprotein profiles in adults with growth hormone deficiency?

Structured PICO

Does recombinant human growth hormone treatment alter lipid and apolipoprotein profiles in adults with growth hormone deficiency?

Population

9 adults (1 woman, 8 men, age range 34-58 years) with adult-onset pituitary insufficiency (duration ≥ 1 year) treated for pituitary tumors, receiving replacement therapy with thyroid hormones, glucocorticoids, and gonadal steroids.

Intervention

Recombinant human growth hormone (0.25-0.5 units/kg per week subcutaneously given each evening) for 6 months.

Comparator

Placebo (crossover design).

Outcome

Fasting serum levels of cholesterol, triglycerides, high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, apolipoproteins A-I, B, and E, and lipoprotein (a) measured before and after 6 and 26 weeks of treatment.surrogate

Growth hormone replacement therapy in adults with pituitary insufficiency significantly increases both atherogenic Lipoprotein (a) and anti-atherogenic HDL cholesterol concentrations.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

GH replacement raises both Lp(a) and HDL; warrants lipid monitoring in GHD adults and leaves net CV risk open.

Cite This Study

Edén et al. (1993) studied this question.

synapsesocial.com/papers/6a7a20cce357fbdac5895f62 https://doi.org/10.1161/01.atv.13.2.296

View Full Paper

Ask AI

Bookmark